NCT00048620
MPS VI, Mucopolysaccharidosis VI
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.
All
Any
No
N-acetylgalactosamine 4-sulfatase
Phase 1
Interventional
2000-09
2006-11-03
Novato, California, United States
*required fields
"*" indicates required fields